Vaccines against enterotoxigenic Escherichia coli

References

• Qadri F, Svennerholm A-M, Faruque ASG, Sack RB. Enterotoxigenic Escherichia coli in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention. Clin. Microbiol. Rev.18(3), 465–483 (2005).
   PubMed Web of Science ®Google Scholar
• Wenneras C, Erling V. Prevalence of enterotoxigenic Escherichia coli-associated diarrhoea and carrier state in the developing world. J. Health Popul. Nutr.22(4), 370–382 (2004).
   PubMed Web of Science ®Google Scholar
• Qadri F, Saha A, Ahmed T, Tarique A, Begum Y, Svennerholm A-M. Disease burden due to enterotoxigenic Escherichia coli (ETEC) in the first two years of life in an urban community in Bangladesh. Infect. Immun.75(8), 3961–3968 (2007).
   PubMed Web of Science ®Google Scholar
• Qadri F, Khan A. Abu Syed G et al. Enterotoxigenic Escherichia coli and V. cholerae diarrhoea, Bangladesh 2004. 11(7), 1104–1107 (2005).
   Google Scholar
• Jiang ZD, Lowe B, Verenkar MP et al. Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay). J. Infect. Dis.185(4), 497–502 (2002).
   PubMed Web of Science ®Google Scholar
• Brown K.H. Diarrhea and malnutrition. J. Nutr.133(1), 328S–332S (2003).
   Google Scholar
• Petri WA Jr, Miller M, Binder HJ, Levine MM, Dillingham R, Guerrant RL. Enteric infections, diarrhea, and their impact on function and development. J. Clin. Invest.118(4), 1277–1290 (2008).
   PubMed Web of Science ®Google Scholar
• Levine MM, Svennerholm A-M. Immunoprophylaxis and immunologic control. In: Travelers’ Diarrhea (Chapter 23, 2nd Edition). Ericsson C, DuPont H, Steffen R (Eds). BC Decker Inc., Hamilton, OR, Canada 215–232 (2008).
   Google Scholar
• Sánchez J, Holmgren J. Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhoea. Curr. Opin. Immunol.17(4), 388–398 (2005).
   PubMed Web of Science ®Google Scholar
• Wolf MK. Occurrence, distribution, and associations of O and H serogroups, colonization factor antigens, and toxins of enterotoxigenic Escherichia coli. Clin. Microbiol. Rev.10(4), 569–584 (1997).
   PubMed Web of Science ®Google Scholar
• Svennerholm AM, Steele D. Microbial–gut interactions in health and disease. Progress in enteric vaccine development. Best Pract. Res. Clin. Gastroenterol.18(2), 421–445 (2004).
   PubMed Web of Science ®Google Scholar
• Sjöling A, Wiklund G, Savarino SJ, Cohen DI, Svennerholm AM. Comparative analyses of phenotypic and genotypic methods for detection of enterotoxigenic Escherichia coli toxins and colonization factors. J. Clin. Microbiol.45(10), 3295–3301 (2007).
   PubMed Web of Science ®Google Scholar
• Gaastra W, Svennerholm A-M. Colonization factors of human enterotoxigenic Escherichia coli (ETEC). Trends Microbiol.4(11), 444–452 (1996).
   PubMed Web of Science ®Google Scholar
• Jansson L, Tobias J, Lebens M, Svennerholm A-M, Teneberg S. Glycosphingolipid binding specificity of colonization factor antigen I from enterotoxigenic Escherichia coli. Infect. Immun.74(6), 3488–3497 (2006).
   PubMed Web of Science ®Google Scholar
• Anantha RP, McVeigh AL, Lee LH et al. Evolutionary and functional relationships of colonization factor antigen I and other class 5 adhesive fimbriae of enterotoxigenic Escherichia coli. Infect. Immun.72(12), 7190–7201 (2004).
   PubMed Web of Science ®Google Scholar
• Savarino S, Poole S, Sincock A et al. Progress towards development of an adhesion-based vaccine against enterotoxigenic E. coli. Presented at: The 4th International Conference on Vaccines for Enteric Diseases. VED 2007, Lisbon, Portugal, 25–27 April 2007.
   Google Scholar
• Shaheen HI, Khalil SB, Rao MR et al. Phenotypic profiles of enterotoxigenic Escherichia coli associated with early childhood diarrhea in rural Egypt. J. Clin. Microbiol.42(12), 5588–5595 (2004).
   PubMed Web of Science ®Google Scholar
• Begum YA, Talukder KA, Nair GB et al. Comparison of enterotoxigenic Escherichia coli isolated from surface water and diarrhoeal stool samples in Bangladesh. Can. J. Microbiol.53(1), 19–26 (2007).
   PubMed Web of Science ®Google Scholar
• Qadri F, Ahmed T, Ahmed F et al. Mucosal and systemic immune responses in patient with diarrhoea due to CS6-expressing enterotoxigenic Escherichia coli. Infect. Immun.75(5), 2269–2274 (2007).
   Google Scholar
• Qadri F, Ahmed F, Ahmed T, Svennerholm A-M. Homologous and cross-reactive immune responses to enterotoxigenic Escherichia coli colonization factors in Bangladeshi children. Infect. Immun.74(8), 4512–4518 (2006).
   Google Scholar
• Rao MR, Wierzba TF, Savarino SJ et al. Serologic correlates of protection against enterotoxigenic Escherichia coli diarrhoea. J. Infect. Dis.191(4), 562–570 (2005).
   PubMed Web of Science ®Google Scholar
• Savarino SJ, Hall ER, Bassily S et al. Introductory evaluation of an oral, killed whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Egyptian infants. Pediatr. Infect. Dis. J.21(4), 322–330 (2002).
   PubMed Web of Science ®Google Scholar
• Tobias J, Andersson K, Bialik A, Cohen D. Preexisting antibodies to homologous colonization factors and heat-labile toxin in serum, and the risk to develop enterotoxigenic Escherichia coli-associated diarrhea. Diagn. Microbiol. Infect. Dis.60(2), 229–231 (2008).
   PubMed Web of Science ®Google Scholar
• Steinsland H, Valentiner-Branth P, Gjessing HK, Aaby P, Mølbak K, Sommerfelt H. Protection from natural infections with enterotoxigenic Escherichia coli: longitudinal study. Lancet362(9380), 286–291 (2003).
   PubMed Web of Science ®Google Scholar
• McKenzie R, Bourgeois AL, Frech SA et al. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine25(18), 3684–3691 (2007).
   PubMed Web of Science ®Google Scholar
• Frech S, Glenn G, Bourgeois AL et al. Use of a patch containing heat-labile toxin from Escherichia coli against tavellers diahrrhoea: a Phase II, randomized, double-blind, placebo-controlled field trial. Lancet371(9629), 2019–2025 (2008).
   PubMed Web of Science ®Google Scholar
• Bourgeois AL, Halpern J, Grahek SL et al. Vaccination of travellers to Guatemala and Mexico with an oral killed vaccine for enterotoxigenic Escherichia coli (ETEC). Presented at: The 4th International Conference on Vaccines for Enteric Diseases. VED 2007, Lisbon, Portugal, 25–27 April 2007.
   Google Scholar
• Clemens JD, Sack DA, Harris JR et al. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large scale field trial. J. Infec. Dis.158(2), 372–377 (1988).
   PubMed Web of Science ®Google Scholar
• Peltola H, Siitonen A, Kyronseppa H et al. Prevention of travellers’ diarrhoea by oral B-subunit/whole-cell cholera vaccine. Lancet338(8778), 1285–1289 (1991).
   PubMed Web of Science ®Google Scholar
• López-Gigosos R, García-Fortea P, Reina-Doña E, Plaza-Martín E. Effectiveness in prevention of travellers’ diarrhoea by an oral cholera vaccine WC/rBS. Travel Med. Infect. Dis.5(6), 380–384 (2007).
   PubMedGoogle Scholar
• Walker RI, Steele D, Aguado T. Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic E. coli (ETEC) disease. Vaccine25, 2545–2566 (2007).
   PubMed Web of Science ®Google Scholar
• WHO. Enterotoxigenic Escherichia coli: advances in technical and laboratory aspects of research and development of vaccines. Wkly Epidemiol. Rec.83(10), 92–95 (2008).
   Google Scholar
• Katz DE, DeLorimier AJ, Wolf MK et al. Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen. Vaccine21(5–6), 341–346 (2003).
   PubMed Web of Science ®Google Scholar
• Güerena-Burgueno F, Hall ER, Taylor DN et al. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect. Immun.70(4), 1874–1880 (2002).
   PubMed Web of Science ®Google Scholar
• Glenn GM, Villar CP, Flyer DC et al. Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum. Infect. Immun.75, 2163–2170 (2007).
   PubMed Web of Science ®Google Scholar
• Jobling M, Rasulova F, Poole St et al. Optimized production and evaluation of pilus adhesin plus enterotoxin B subunit chimers as novel candidate vaccines against diarrhea caused by enterotoxigenic E. coli. Cholerae and other bacterial enteric infections. Presented at: United States–Japan Cooperative Medical Science program. 42nd Annual Joint Panel Meeting, Austin, TX, USA, 5–7 December 2007.
   Google Scholar
• Mason HS, HaqTA, Clements JD, Arntzen CJ. Edible vaccine protects mice against Escherichia coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene. Vaccine16(3), 1336–1343 (1998).
   PubMed Web of Science ®Google Scholar
• Tacket CO. Plant-derived vaccines against diarrhoeal diseases. Expert Opin. Biol. Ther.4(5), 719–728 (2004).
   PubMed Web of Science ®Google Scholar
• Evans DG, Evans DJ Jr, Opekun AR, Graham DY. Non-replicating oral whole cell vaccine protective against enterotoxigenic Escherichia coli (ETEC) diarrhea: stimulation of anti-CFA (CFA/I) and anti-enterotoxin (anti-LT) intestinal IgA and protection against challenge with ETEC belonging to heterologous serotypes. FEMS Microbiol. Immunol.1(3), 117–125 (1988).
   Google Scholar
• Svennerholm AM, Holmgren J, Sack DA. Development of oral vaccines against enterotoxinogenic Escherichia coli diarrhoea. Vaccine7(3), 196–198 (1989).
   PubMed Web of Science ®Google Scholar
• Svennerholm A-M, Savarino SJ. Oral inactivated whole cell B subunit combination vaccine against enterotoxigenic Escherichia coli. In: New Generation Vaccines (3rd Edition) . Levine MM, Kaper JB, Rappuoli R, Liu MA, Good MF (Eds). Marcel Decker, NY, USA
   Google Scholar
• Qadri F, Ahmed T, Ahmed F et al. Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi children 18–36 months of age. Vaccine21(19–20), 2394–2403 (2003).
   PubMed Web of Science ®Google Scholar
• Qadri F, Ahmed T, Ahmed F et al. Reduced doses of oral killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine is safe and immunogenic in Bangladeshi infants 6–17 months of age: dosing studies in different age groups. Vaccine24(10), 1726–1733 (2006).
   PubMed Web of Science ®Google Scholar
• Sack DA, Shimko J, Torres O et al. Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. coli diarrhoea of travellers to Guatemala and Mexico. Vaccine25(22), 4392–4400 (2007).
   PubMed Web of Science ®Google Scholar
• Tobias J, Lebens M, Bölin I, Wiklund G, Svennerholm AM. Construction of non-toxic Escherichia coli and Vibrio cholerae strains expressing high and immunogenic levels of enterotoxigenic E. coli colonization factor I fimbriae. Vaccine26(6), 743–752 (2008).
   PubMed Web of Science ®Google Scholar
• Freytag LC, Clements JD. Mucosal adjuvants. Vaccine23(15), 1804–1813 (2005).
   PubMed Web of Science ®Google Scholar
• Cuburu N, Kweon MN, Song JH et al. Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine25(51), 8598–8610 (2007).
   PubMed Web of Science ®Google Scholar
• Turner AK, Terry TD, Sack DA, Londono-Arcila P, Darsley MJ. Construction and characterization of genetically defined aro omp mutants of enterotoxigenic Escherichia coli and premliminary studies of safety and immunogenicity in humans. Infect. Immun.69(8), 4969–4979 (2001).
   PubMed Web of Science ®Google Scholar
• McKenzie R, Bourgeois AL, Engstrom F et al. Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults. Infect. Immun.74(2), 994–1000 (2006).
   PubMed Web of Science ®Google Scholar
• Turner AK, Beavis JC, Stephens JC et al. Construction and Phase I clinical evaluation of the safety and immunogenicity of a candidate enterotoxigenic Escherichia coli vaccine strain expressing colonization factor antigen CFA/I. Infect. Immun.74(2), 1062–1071 (2006).
   PubMed Web of Science ®Google Scholar
• Daley A, Randall R, Darsley M et al. Genetically modified enterotoxigenic Escherichia coli vaccines induce mucosal immune responses without inflammation. Gut56(11), 1550–1556 (2007).
   PubMedGoogle Scholar
• Barry EM, Wang J, Wu T, Davis T, Levine MM. Immunogenicity of multivalent Shigella–ETEC candidate vaccine strains in a guinea pig model. Vaccine24(8), 3727–3737 (2006).
   PubMed Web of Science ®Google Scholar
• Roland KL, Cloninger C, Kochi SK et al. Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli. Vaccine25(51), 8574–8584 (2007).
   PubMed Web of Science ®Google Scholar
• Ziethlow V, Favre D, Viret JF, Frey J, Stoffel MH. Assessment by electron-microscopy of recombinant Vibrio cholerae and Salmonella vaccine strains expressing enterotoxigenic Escherichia coli-specific surface antigens. Clin. Microbiol. Infect.14(3) 282–286 (2008).
   Google Scholar
• Sizemore DR, Roland KL, Ryan US. Enterotoxigenic Escherichia coli virulence factors and vaccine approaches. Expert Rev. Vaccines3(5), 585–895 (2004).
   PubMedGoogle Scholar
• Nagy E. Towards protein based vaccines for the prevention of bacterial diarrhoea. Presented at: The 4th International Conference on Vaccines for Enteric Diseases. VED 2007. Lisbon, Portugal, 25–27 April 2007.
   Google Scholar
• Bölin I, Wiklund G, Qadri F et al. Enterotoxigenic Escherichia coli with STh and STp genotypes is associated with diarrhea both in children in areas of endemicity and in travelers. J. Clin. Microbiol.44(11), 3872–3877 (2006).
   PubMed Web of Science ®Google Scholar
• Åhren C, Jertborn M, Svennerholm AM. Intestinal immune responses to an inactivated oral enterotoxigenic Escherichia coli vaccine and associated immunoglobulin A responses in blood. Infect. Immun.66(7), 3311–3316 (1998).
   PubMed Web of Science ®Google Scholar
• Jertborn M, Åhren C, Svennerholm AM. Dose-dependent circulating immunoglobulin A antibody-secreting cell and serum antibody responses in Swedish volunteers to an oral inactivated enterotoxigenic Escherichia coli vaccine. Clin. Diagn. Lab. Immunol.8(2), 424–428 (2001).
   PubMedGoogle Scholar
• Carpenter CM, Hall ER, Randall R et al. Comparison of the antibody in lymphocyte supernatent (ALS) and ELISPOT assays for detection of mucosal immune responses to antigens of enterotoxigenic Escherichia coli in challenged and vaccinated volunteers. Vaccine24(18), 3709–3718 (2006).
   Google Scholar